ALPHAMELD TECHNOLOGY PLATFORM
Empowering Breakthroughs with Advanced AI Solutions
PLATFORM OVERVIEW
We help our partners by combining the expertise of multitalented drug discovery experts with the most up-to-date technology solutions such as AI, machine learning, and generative AI to guide the development of innovative drugs. Our flagship technology platform, AlphaMeld has been assembled to triangulate the right drug to the right target to the most optimal disease profile. We have been successful in achieving these goals by following an evidence based process.
DRIVING INNOVATION WITH AI, ML, AND GENERATIVE AI
Our advanced platform offers valuable insights by highlighting direct and indirect associations between key entities such as genes and targets, pathways, biomarkers, drugs, and diseases and symptoms, allowing the AlphaMeld discovery platform to extract and provide guidance on the functional direction between entities. This enables the turbocharging of hypothesis generation and prioritization for innovative drug programs by using large-scale information and unprecedented speed to increase the probability of clinical and regulatory success.
It boasts 1,968,753,898 associations between 649,893,375 data points and includes more than 49,000 drugs, 20,000 genes, 30,000 disease/symptoms, 73,000 expression datasets, 1,400 cell types, 483,000 clinical events, and over a billion scientific literature sentences and growing to triangulate disease-target-drug associations.
The most recent addition to the platform is ChatAlphaMeld that is modeled to support functional stakeholders across the drug discovery and development lifecycle.